Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eugene Chardoul

Internal Medicine Flint, MI Medical Doctor

NPI 1154360378 CMS profile 324149

3499 S Linden Rd, Suite 2, Flint, MI 48507

Open in the dashboard

General payments

$5,298

284 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eugene Chardoul of Flint, MI is reported in the CMS Open Payments database as having received $5,298 across 284 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $988 51
2024 General $990 53
2023 General $706 43
2022 General $765 34
2021 General $841 49
2020 General $314 16
2019 General $695 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eugene Chardoul
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Eugene Chardoul were reported at $988. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Eugene Chardoul Internal Medicine median Middle half National median
2019 $695 $159 $48–$570 $163
2020 $314 $119 $33–$402 $114
2021 $841 $135 $37–$521 $132
2022 $765 $141 $42–$496 $149
2023 $706 $149 $45–$519 $160
2024 $990 $154 $47–$537 $164
2025 $988 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,049 70 payments
  2. Otsuka America Pharmaceutical, Inc. $811 40 payments
  3. AstraZeneca Pharmaceuticals LP $609 20 payments
  4. Pfizer Inc. $407 22 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $295 20 payments
  6. Lundbeck LLC $258 12 payments
  7. Novartis Pharmaceuticals Corporation $196 13 payments
  8. Vanda Pharmaceuticals Inc. $186 11 payments
  9. Amgen Inc. $186 11 payments
  10. Sunovion Pharmaceuticals Inc. $159 8 payments
  11. Other $1,143 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,274 282 payments
  2. Education $24 2 payments
Products named General payments · program years 2019–2025
  1. REXULTI Psychiatry $811 40 payments
  2. VRAYLAR $566 45 payments
  3. FARXIGA $449 17 payments
  4. UBRELVY $406 17 payments
  5. XIFAXAN $295 20 payments
  6. REXULTI Psychiatry $258 12 payments
  7. ELIQUIS $235 12 payments
  8. PAXLOVID $191 10 payments
  9. AIRSUPRA $186 2 payments
  10. FANAPT $186 11 payments
  11. Other $2,677 153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 120 drugs

Part D claims

7,617

Median for Internal Medicine: 777

Drug cost

$551,793

Median for Internal Medicine: $73,373

Branded share of claims

28.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 80 $86,834
Rexulti Brexpiprazole Brand 33 $66,894
Vraylar Cariprazine Hcl Brand 27 $50,570
Trulicity Dulaglutide Brand 31 $40,087
Januvia Sitagliptin Phosphate Brand 34 $34,965
Xarelto Rivaroxaban Brand 30 $31,568
Farxiga Dapagliflozin Propanediol Brand 38 $30,027
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 19 $29,063
Entresto Sacubitril/Valsartan Brand 19 $20,122
Jardiance Empagliflozin Brand 13 $13,629

The 10 drugs with the highest cost, of 120 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$80,550

Of which drugs: $2,683

Medicare patients

133

Average age 75

Services billed

1,720

61 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 41%
Depression 29%
COPD 28%
Ischemic heart disease 27%
Diabetes 23%
Atrial fibrillation 22%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 30 30 $2,376
Injection, ceftriaxone sodium, per 250 mg J0696 Office 23 128 $43

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $105
  • Otsuka America Pharmaceutical, Inc. $79
$184 33 —
VRAYLAR
  • AbbVie, Inc. $174
$174 27 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $145
$145 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $50
$50 — —
UBRELVY
  • AbbVie, Inc. $49
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

284 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record